Research programme: anthrax therapies - Elusys

Drug Profile

Research programme: anthrax therapies - Elusys

Alternative Names: ETI-205

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elusys Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 15 Dec 2006 Elusys has extended the CRADA with the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
  • 07 Mar 2005 This programme is still in active development
  • 11 Oct 2000 Preclinical development for Anthrax in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top